Annals of the rheumatic diseases
-
Multicenter Study
Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Increased expression of B cell activating factor (BAFF or B lymphocyte stimulator) may explain the B cell activation characteristic of primary Sjögren's syndrome (pSS). ⋯ These encouraging results justify future randomised controlled trials of belimumab in a selected target population of pSS patients most likely to benefit from treatment.